Study
| Double-blind Phase III trial |
| Untreated intermediate-risk or high-risk DLBCL |
| Polatuzumab-R-CHP vs R-CHOP |
Efficacy
| 2 years PFS: 76.7% vs 70.2% (HR:0.73 95% Cl 0.57-0.95 p=0.02) |
| 2 years OS: 88.7% vs 88.6% (HR:0.94 95% Cl 0.65-1.37 p=0.75) |
Safety
| Any grades AEs: All 97.9% vs 98.4%, |
| Grade >=3 AEs: 60.7% vs 59.8% |
| Serious AEs:34.0% vs 30.6% |
| Grade 5 AEs: 3.0% vs 2.3% |
N Engl J Med 2022; 386:351-363
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
http://doi.org/10.1056/NEJMoa2115304
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022
